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Interferon-regulatory factors (IRFs) are a family of
transcription factors (TFs) that translate viral recogni-
tion into antiviral responses, including type I inter-
feron (IFN) production. Dengue virus (DENV) andother
clinically important flaviviruses are suppressed by
type I IFN. While mice lacking the type I IFN receptor
(Ifnar1/) succumb to DENV infection, we found
that mice deficient in three transcription factors
controlling type I IFN production (Irf3/ Irf5/ Irf7/
triple knockout [TKO]) survive DENV challenge. DENV
infection of TKO mice resulted in minimal type I IFN
production but a robust type II IFN (IFN-g) response.
Using loss-of-function approaches for various
molecules, we demonstrate that the IRF-3-, IRF-5-,
IRF-7-independent pathway predominantly utilizes
IFN-g and, to a lesser degree, type I IFNs. This
pathway signals via IRF-1 to stimulate interleukin-12
(IL-12) production and IFN-g response. These results
reveal a key antiviral role for IRF-1 by activating both
type I and II IFN responses during DENV infection.
INTRODUCTION
Interferon-regulatory factors (IRFs) are members of a small
group of transcription factors (TFs) that link microbial recognition
to production of type I interferons (IFNs) and other antiviral
responses (Ikushima et al., 2013; Honda and Taniguchi, 2006).
Targeted genetic deletion of IRF transcription factors in mice
increases susceptibility to pathogens, particularly viruses
(Tamura et al., 2008). IRF-3 and IRF-7 are the primary regulators
in the canonical model of type I IFN (IFN-ab) signaling and thus
essential for viral control (Honda and Taniguchi, 2006; Honda
et al., 2005). Recognition of viral pathogen-associated molecular
patterns (PAMPs) by pattern recognition receptors (PRRs)
results in activation and nuclear translocation of IRF-3 and/or
IRF-7, which leads to the induction of Ifnb1. Secreted IFN-beta
(IFN-b) binds to a type-I-IFN-specific heterodimeric receptor,
Ifnar1/Ifnar2 (IFNAR), activating a JAK-STAT signaling cascade
and the induction of hundreds of interferon-stimulated genes
(ISGs) that suppress viral pathogens by many mechanisms
(Liu et al., 2012; Rusinova et al., 2013; Takaoka and Yanai,
2006; Diamond and Gale, 2012; MacMicking, 2012; Schoggins
et al., 2011) and create a feed-forward amplification loop
of IFN signaling by increasing expression of IRF-7 (Honda
and Taniguchi, 2006; Honda et al., 2005). Interferon-gamma
(IFN-g), the only type II IFN, also demonstrates antiviral activity
and defends against many infections (Platanias, 2005). Mice
with targeted genetic deficiencies in IFN-g signaling show
increased susceptibility to certain intracellular bacterial, proto-
zoan, and viral infections (John et al., 2002; Harty and Bevan,
1995; Dalton et al., 1993; Huang et al., 1993; Jouanguy et al.,
1999; Maloney et al., 2012; Schroder et al., 2004; Chesler and
Reiss, 2002). IFN-g, analogous to type I IFNs, binds a type-spe-
cific heterodimeric receptor complex, Ifngr1/Ifngr2 (IFNGR), and
activates a JAK-STAT signaling cascade, resulting in the induc-
tion of a set of ISGs that partially overlaps with the type I IFN
response. In contrast to type I IFNs that are secreted directly
by virally infected cells, IFN-g is produced principally by natural
killer (NK) cells and activated T cells in response to secreted cy-
tokines such as interleukin-12 (IL-12) and IL-18 (Schoenborn and
Wilson, 2007; Okamura et al., 1995, 1998).
In addition to IRF-3 and IRF-7, which are considered themaster
regulators of type I IFN production, both IRF-1 and IRF-5 can
induce type I IFN genes (Honda and Taniguchi, 2006; Fujita
et al., 1989; Barnes et al., 2001; Yie et al., 1999). IRF-1, IRF-3,
IRF-5, and IRF-7 contribute to the suppression of viruses, often-
times in a cell-type- and viral-specific manner (Brien et al., 2011;
Chen et al., 2013; Lazear et al., 2013). Because of the central
importance of IRF transcription factors in viral defense, many
pathogenic viruses have evolved mechanisms to suppress IRF
signaling (Barro and Patton, 2007; Dalrymple et al., 2015; Devaraj
et al., 2007; Zhu et al., 2002; Robertson et al., 2014). How specific
IRFs activate canonical and non-canonical host antiviral
defense pathways in response to specific viruses in vivo is still
poorly understood but potentially depends on viral tropism
and immune evasion mechanisms used by individual viruses
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(Daffis et al., 2009; Rudd et al., 2012; Schilte et al., 2012;
Steinberg et al., 2009).
Type I and II IFNs play key roles in controlling acute
dengue virus (DENV) and other flavivirus infections in humans
(Navarro-Sa´nchez et al., 2005). IFN-a/b or IFN-g protects
against DENV infection of human cells in vitro (Diamond
et al., 2000; Ho et al., 2005), and humans infected with DENV
have high levels of circulating IFN-a (Kurane et al., 1993; Libraty
et al., 2002) and IFN-g (Chakravarti and Kumaria, 2006; Chen
et al., 2005, 2006; Kurane et al., 1991; Nguyen et al., 2004).
A critical role for IFNs in the protection against DENV severe
disease is supported by studies showing children with dengue
shock syndrome have substantially less induction of ISGs than
children with milder DENV infection (Clyde et al., 2006). Simi-
larly, adults in Taiwan who survived DENV infection, but not
those who succumbed to DENV infection, had significantly
higher levels of circulating IFN-g than controls (Chen et al.,
2006). DENV is highly sensitive to type I IFN responses in
mice and, accordingly, causes little disease in wild-type (WT)
animals but rapid mortality in mice lacking IFNAR expression
(Orozco et al., 2012; Makhluf et al., 2013). Remarkably, Irf3/
Irf7/ double-knockout (DKO) mice survive DENV infection
despite developing high levels of viremia (Chen et al., 2013;
Shresta et al., 2004), suggesting that an alternative antiviral
response is produced in an IRF-3- and IRF-7-independent
manner (Chen et al., 2013; Orozco et al., 2012; Shresta et al.,
2004). As IRF-5 can contribute to type I IFN signaling and
help protect DKO mice from infection with a closely related fla-
vivirus, West Nile virus (WNV) (Schoenemeyer et al., 2005), we
hypothesized that IRF-5 also might contribute to the resistance
of DKO mice to severe DENV infection.
To test this hypothesis, we infected Irf3/ Irf5/ Irf7/ triple-
knockout (TKO) mice with DENV and unexpectedly found that all
TKO mice survived, whereas all congenic Ifnar1/ mice died
from infection by day 6. Transcriptional profiles of DKO and
TKO splenocytes showed activation of the IL-12/IFN-g/IRF-1
signaling axis that was not present in Ifnar1/ mice. Blocking
IL-12 or IFN-g signaling or genetic deletion of IRF-1 in TKO
mice (Irf1/ Irf3/ Irf5/ Irf7/ quadruple knockout [QKO])
infected with DENV led to severe disease and death, confirming
the importance of this alternative pathway in DENV resistance.
DENV infection in vitro of TKO macrophages demonstrated
selective upregulation of Il12b that encodes the IL12p40 subunit
of the cytokine IL-12, which is known to promote IFN-g
production by NK and T cells. Finally, IFNAR blockade in TKO
mice and macrophages revealed a small albeit significant role
for type I IFNs in mediating host defense against DENV.
Collectively, our results establish an IRF-3, IRF-5, and IRF-7
(IRF-3/5/7)-independent alternative pathway of viral resistance
that utilizes IRF-1 to stimulate protective IFN-g and, to a lesser
extent, type I IFN responses against DENV.
RESULTS
MiceDeficient in IRF-3, IRF-5, and IRF-7AreResistant to
Severe DENV Infection
To test the hypothesis that IRF-5 is involved in the IRF-3 and
IRF-7-independent pathway of DENV resistance, WT, DKO,
TKO, and Ifnar1/ mice were infected with DENV2 (strain 221)
and followed for mortality, weight loss, and clinical score (War-
field et al., 2015). Unexpectedly, similar to WT (B6) and DKO
mice, all TKO mice survived infection, whereas Ifnar1/ mice
uniformly developed lethal disease by day 6 post-infection (p.i.)
(Figure 1A). After the first day of infection, WT mice steadily
gained weight and had higher average body weights than either
DKO or TKO mice on days 2–4 p.i. (p < 0.0001) (Figure 1B). DKO
and TKO mice initially lost weight but recovered after day 2 p.i.,
whereas Ifnar1/ mice lost a substantial amount of weight and
had lower mean body weights on most days after day 2 p.i. than
DKO and TKOmice (p < 0.05 on day 1 and p < 0.0001 on days 3,
4, and 6). Additionally, Ifnar1/mice had higher disease scores
by day 2 p.i. thanWT and higher disease scores by day 4 p.i. than
DKO and TKOmice, and these differences were maintained until
all Ifnar1/ mice had succumbed to infection (Figure 1C).
To determine the contributions of IRF-3, IRF-5, and IRF-7 to
the kinetics of viral clearance, DENV was measured in blood,
spleen (the initial target organ of DENV in this model), kidney,
and liver (subsequent target organs of DENV) at 24 and 72 hr
p.i. After 24 and 72 hr of infection, DKO, TKO, and Ifnar1/
mice had significantly higher levels of DENV RNA than WT
mice in all tissues examined (Figures 1D–1G). At 24 hr p.i., there
was a minimal (4-fold, p < 0.01) increase in infectious virus in
DKO compared to Ifnar1mice in the spleen, but no other differ-
ences were observed among DKO, TKO, and Ifnar1/ mice.
However, at 72 hr p.i., DKO and TKO mice had lower levels
(>10,000-fold, p = 0.0001 and >390-fold, p < 0.03 respectively)
of viremia then Ifnar1/ mice (Figure 1D). In the spleen and
kidney, a pattern of progressively higher viral burdens emerged
in DKO, TKO, and Ifnar1/ mice, respectively (Figures 1E
and 1F). In the liver, DKO and TKO mice had lower (120-fold,
p < 0.0001 and 30-fold, p < 0.002) viral loads than Ifnar1/
mice (Figure 1G). Collectively, these data demonstrate that
IRF-3, IRF-5, and IRF-7 and a functional type I IFN response
are necessary to restrict early DENV replication in different
organs. These results also demonstrate the presence of a
delayed IRF-3, IRF-5, and IRF-7-independent antiviral response
that controls DENV infection and dissemination in lymphoid and
non-lymphoid tissues and improves clinical disease outcome.
An IRF-3, IRF-5, and IRF-7-Independent Pathway
Contributes to Cell-Intrinsic Antiviral Resistance in
Bone-Marrow-Derived Macrophages
DENV infects macrophage populations in the spleen and other
lymphoid tissues before spreading to resident and infiltrating
macrophages in non-lymphoid tissues (Prestwood et al., 2012).
To determine whether the differences in DENV phenotypes
between TKO and Ifnar1/ mice in vivo could reflect disparate
cell-intrinsic antiviral responses, bone-marrow-derived macro-
phages (BMDMs) from WT, TKO, and Ifnar1/ mice were
infected with DENV, and yield of secreted virus in the culture
supernatant was measured by focus-forming unit (FFU) assay.
DENV established productive infection in BMDMs derived from
TKO and Ifnar1/, but not WT, mice (Figures 2A and S1A).
Although DENV replicates in TKO BMDMs, less virus was
produced compared to Ifnar1/ cells at 24, 48, and 72 hr p.i.
(12-fold, p < 0.0003; 4-fold, p < 0.05; and 10-fold, p < 0.001,
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respectively). Moreover, there was substantially less virus
produced during infection of DKO macrophages than TKO
macrophages at 24 and 48 hr p.i. (70-fold, p < 0.0002 and
25-fold, p < 0.007, respectively; Figure 2B). The progressive
increase in susceptibility to DENV productive infection in DKO,
TKO, and Ifnar1/macrophages was similar to that seen in vivo
at 72 hr p.i. To further compare the relative resistance of DKO
and TKO BMDMs to DENV infection, we measured the expres-
sion of Ifnb1 and the ISGs Mx1 and Ifit1. Although we did not
detect a statistically significant upregulation of Ifnb1 in DKO or
TKO BMDMs, we did measure a significantly greater induction
of both Mx1 and Ifit1 in DENV-infected DKO BMDMs than in
DENV-infected TKO BMDMs (Figures 2C and S1B). Additionally,
TKO BMDMs were infected with DENV in the presence or
absence of an IFNAR blocking antibody (IFNARAb) that inhibits
type I IFN signaling. IFNAR blockade significantly increased
the susceptibility of TKO BMDMs to DENV infection (Figure 2D).
These results show that IRF-3, IRF-5, and IRF-7 contribute to
macrophage resistance to DENV infection and that despite the
lack of all three of these transcription factors, BMDMs still
make low levels of type I IFN that contribute to DENV resistance.
DKO and TKO Mice Upregulate IRF-1- and
IFN-g-Associated Transcriptional Programs
To determine the levels of type I IFN signaling in DKO and TKO
mice and potentially identify alternative mechanisms for the
delayed IRF-3, IRF-5, and IRF-7-independent pathway of
immune response to DENV infection in vivo, we infected WT,
Ifnar1/, DKO, and TKO mice and prepared total splenocytes
at 6 and 24 hr p.i. for genome-wide transcriptional sequencing
(RNA sequencing [RNA-seq]). Gene expression profiles deter-
mined by RNA-seq from independent biological replicates
Figure 1. Lethality and Clinical Disease Manifestations after DENV Infection
(A–C) WT, DKO, TKO, and Ifnar1/ mice were infected with 5 3 106 FFU of DENV2 strain 221 with antibody-dependent enhancement (ADE), and lethality (A),
percent weight loss (B), and clinical disease scores (C) were assessed daily for 10 days. Survival was compared between all groups and Ifnar1/mice showed
less survival than all other groups tested (log-rank test, p < 0.0001). Data are expressed asmean percent weight loss and clinical scores that were compared daily
by one-way ANOVA or non-parametric (Kruskal-Wallis) ANOVA with multiple correction, respectively.
(D–G) Levels of viral RNA in the serum (D), spleen (E), kidney (F), and liver (G) at 24 and 72 hr p.i. were determined by qRT-PCR. Data are presented as mean log10
viral GE per mL of serum or per copy of 18S ribosomal RNA of tissues for six to eight mice from two independent experiments. The lower limit of detection is
denoted by a dotted line. Viral titers between the gene-deficient and WT mice were compared by ANOVA with Tukey’s multiple comparisons tests.
Asterisks indicate differences that are statistically significant (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05).
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revealed substantial differences in gene expression patterns
among mouse genotypes (Figures 3A and 3B). A chord diagram
that depicts connections between individual genes contained
in multiple groups demonstrates a broader scope of gene upre-
gulation at 6 hr p.i. (fold change [FC] >1.5 and false discovery rate
[FDR] <0.05) in splenocytes from WT (262 genes) and DKO
(472 genes) mice than in those from TKO (55 genes) and Ifnar1/
(2 genes) mice, with minimal overlap in induced genes between
genotypes (Xia et al., 2014, 2015) (Figure 3A). A broader and
more overlapping gene signature (FC >2 and FDR <0.05) was
evident after 24 hr of infection in all genotypes (Figure 3B).
Upregulated transcripts in DKO and TKO mice were highly
similar, and over 80% of the genes induced in DKO cells were
also upregulated in TKO cells (Figures 3B and S2A).
Clustering of differentially expressed genes (FC >2 across time
points or genotypes) identified three clusters (clusters 1–3)
showing temporal and genotype-specific patterns of expression
(Figure 3C). Cluster 3 is composed of genes strongly induced by
6 hr p.i. and throughout the response of WT mice, whereas
clusters 1 and 2 are composed of genes strongly (cluster 1) or
moderately (cluster 2) induced in DKO and TKO mice in a more
delayed manner. Gene ontology and pathway analysis of clus-
ter-3-containing genes were enriched for terms related to clas-
sical antiviral responses, including viral PRRs and type I IFN
stimulation (Figure 3D). In contrast, clusters 1 and 2 demon-
strated enrichment for ontologies and pathways related more
generally to inflammatory processes such as immune responses,
response to wounding, apoptosis, and cytokine signaling.
Individual gene analysis of upregulated genes in cluster 3
identified type I IFN genes (Ifnb1, Ifna4, and Ifna2) in addition
to well-characterized ISGs involved in viral recognition and
restriction (Mx and Oas genes, Ddx58/RIG-I, Isg15, Eif2ak2/
PKR, and Rsad2/Viperin) (Figure 3E). Within cluster 3, type I
IFN genes (Ifnb1, Ifna4, and Ifna2) were strongly induced in
Ifnar1/mice, but there was little to no induction of ISGs, as ex-
pected. Additionally, there was mild upregulation of some ISGs
(Ddx58, Isg15, Eif2ak2, and Oas1b) in cluster 3 in DKO and
TKO mice at 24 hr despite no detectable upregulation of type I
IFN encoding genes.
Cluster-1-containing genes were strongly upregulated in
DKO and TKO mice, but not in WT or Ifnar1/ mice, at 24 hr
p.i.; these included AP-1 transcription factors (Fos and Jun)
and signal-dependent transcription factors (SDTFs) (Stat1 and
Irf1) that regulate innate immune responses and the pro-
inflammatory cytokines IL-6, tumor necrosis factor (TNF-a),
IL-1b, and IFN-g. Additionally, many components of the IL-
12/IFN-g signaling axis involved in macrophage host defense,
including Irf1, Ifng, Il12b, and Il12rb1, as well as multiple IRF1
target genes (Il12b, Il12rb1, Nos2, Tap1, Cdkn1a, Gbp2,
Socs1, Tnf, and Il6), were present in cluster 1 (Honda and
Taniguchi, 2006; Kano et al., 2008; Maruyama et al., 2003;
Briken et al., 1995; Madonna et al., 2010; Sance´au et al.,
1995; Vila-del Sol et al., 2008). These data are consistent
with prior findings in DENV-infected DKO mice that showed
higher levels of circulating IFN-g, IL-6, IL-12p70, and TNF-a
after 24 hr (Chen et al., 2013). University of California Santa
Cruz (UCSC) browser shots of genes from clusters 3 (Mx1)
and 1 (Ifng and Irf1) demonstrate the distinct patterns of
expression in WT compared to DKO and TKO mice (Figures
3F, S2B, and S2C).
Figure 2. Bone-Marrow-Derived Macro-
phage Response to DENV Infection
(A and B) BMDMs from WT, TKO, and Ifnar1/
mice (A) or DKO and TKO mice (B) were infected
with DENV2 S221 under ADE conditions (MOI of
0.5), and viral replication was measured by focus-
forming assay (FFA). Data represent the mean ±
SEMof three independent experiments. The dotted
line represents the limit of detection of the assay.
(C) BMDMs from DKO and TKO mice were
infected with DENV2 S221 under ADE conditions
(MOI of 0.5), RNA was isolated at 24 hr after
infection, and relative expression of the indicated
target genes was measured by qRT-PCR and
normalized to Rplp0. Data represent the average
of three independent experiments (black circles)
and are expressed as the mean ± SEM.
(D) TKO BMDMs were infected as in (A) and
(B) ± IFNAR-blocking antibody (Ab) (clone MAR1-
5A3) added 12 hr prior to infection and viral
replication measured by FFA. Data represent the
mean ± SEM of two independent experiments.
Log10 viral FFU from gene-deficient, IFNAR-
blocking-Ab-treated or WT BMDMs were com-
pared to TKO using two-way ANOVA with
correction for multiple comparisons.
Relative gene expression (C) was compared using
one-way ANOVA with Tukey’s correction for
multiple comparisons. Asterisks indicated differ-
ences that were statistically significant (****p <
0.0001; ***p < 0.001; **p < 0.01; *p < 0.05).
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De novo motif enrichment analysis of promoters from clus-
ter 1 genes identified motifs known to bind IRF-1 and
nuclear factor kB (NF-kB) as the most enriched sequences
(Figure 3G). In contrast, analysis of cluster 3 genes identified
the IFN-stimulated response element (ISRE) motif, where
ISGF3 binds and promotes ISG expression following type I
Figure 3. Gene Expression Analysis of Splenocytes during DENV Infection
(A and B) Chord diagram of significantly upregulated genes after DENV infection determined by RNA-seq analysis of total splenocytes and their overlap in WT,
Ifnar1/, DKO, and TKO mice at 6 hr p.i. (A) and 24 hr p.i. (B).
(C) k-means cluster analysis of differentially expressed genes in WT, Ifnar1/, DKO, and TKO splenocytes at baseline and 6 and 24 hr p.i.
(D) GO and KEGG pathway terms significantly enriched in genes contained in clusters 1–3. Log Benjamini-corrected p values are shown.
(E) Examples of genes contained within clusters 1–3. Known IRF-1 target genes are highlighted in blue.
(F) UCSC genome browser images of Ifng gene from indicated genotypes at 24 hr p.i.
(G) Motifs enriched in the promoters of genes found in cluster 1 or 3.
(H) WT and TKOmice were infected with 53 106 FFU of DENV2 strain 221 with ADE and RNAwas isolated at 24 hr after infection from total splenocytes. Relative
expression of the indicated target geneswasmeasured by qRT-PCR and normalized toRplp0. Data represent the average expression level in 6mock-treatedWT,
10 DENV-infected WT, 6 mock-treated TKO, and 6 DENV-infected TKO spleens expressed as the mean ± SEM. Relative gene expression was compared using
one-way ANOVA with Tukey’s correction for multiple comparison. Asterisks indicated differences that were statistically significant (****p < 0.0001; ***p < 0.001;
**p < 0.01; *p < 0.05).
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IFN signaling, as the most enriched sequence in promoter
proximal regions.
A first-order interaction network based on genes significantly
upregulated (FC >2 and FDR <0.05) in both DKO and TKO at
24 hr p.i. identified Irf1, Irf8, Jun, Fos, Cebpb, Stat3, and
Myd88 as hub nodes with high degrees of connectivity within
the network (Figure S3A). Analysis of upregulated genes within
the network showed enrichment for the reactome categories
immune response (57 nodes, p = 5.18e-18) and IFN signaling
(14 nodes, p = 1.13e-8). The immune response module
contained many of the same hubs as the original network,
with the addition of NFKB1 and RELA showing high degrees
of centrality in this subnetwork (Figure S3B). Similar to the
cluster-based analysis, the IFN response subnetwork contained
many genes involved in the IL-12/IFN-g signaling axis, including
Irf8, Irf1, Ifng, Il12rb1, and Il12b (Figure S3C).
In addition to the RNA-seq analysis, we measured Ifnb1,Mx1,
Ifng, Irf1, and Nos2 expression in splenocytes from mock- and
DENV-infected WT and TKO mice by qRT-PCR. We detected a
small but inconsistent upregulation of Ifnb1 in splenocytes
from DENV-infected TKO mice (Figure 3H). Consistent with the
RNA-seq results, we detected significantly more induction of
Mx1 in DENV-infected splenocytes from WT mice than TKO
mice but greater upregulation of Ifng, Irf1, and Nos2 in spleno-
cytes from TKO mice relative to WT animals (Figure 3H).
Taken together, our RNA-seq and qRT-PCR analyses of differ-
ential gene expression provided the anticipated result that WT
mice upregulate type I IFN genes and activate a robust and early
classical ISG response, whereas Ifnar1/ mice induce genes
encoding type I IFNs but cannot produce ISGs. In comparison,
DKO and TKO mice appeared to mount a low-level type I IFN
response with a robust induction of an alternative inflammatory
transcriptional program that includes the IL-12/IFN-g/IRF-1
signaling axis and NF-kB signaling pathways. Since DKO and
TKO mice seemed to activate these alternative programs and
Ifnar1/ mice do not, we hypothesized that the IL-12/IFN-g/
IRF-1 responses could contribute to protection against lethal
DENV infection.
IL-12 and IFN-g Contribute to DENV Resistance in
TKO Mice
Activated macrophages and dendritic cells can secrete IL-12,
which promotes the development of Th1 responses and induces
IFN-g secretion by NK and T cells. As the genes encoding the
IL-12p40 subunit, IL-12 receptor, and IFN-g were upregulated
in splenocytes from DENV-infected DKO and TKO mice, we
hypothesized that IL-12 contributed to IFN-g production and
resistance to severe DENV disease in TKO mice. To determine
the contribution of IL-12 to DENV resistance in TKO mice, we
injected IL-12p40 neutralizing antibody (IL12p40Ab) or isotype
control antibody (Ctrl Ab) into TKO mice infected with DENV
and monitored mortality, weight loss, and clinical disease score
(Figures 4A–4C). In two experiments, 50% of TKO mice injected
with IL12p40Ab died (p = 0.055) and manifested significantly
increased weight loss starting at day 5 p.i. and a worse clinical
score at day 8 compared to isotype-control-injected TKO mice
(Figures 4B and 4C), demonstrating a role for IL-12 in protection
against DENV infection in TKO mice.
To test the hypothesis that IFN-g has a key role in TKO resis-
tance to DENV-induced mortality, we infected Ifnar1/ mice
and two groups of TKOmice, one injected with an IFN-g neutral-
izing antibody (IFNgAb) and the other with Ctrl Ab, with DENV
and monitored mortality, weight loss, and clinical score (Fig-
ure 4D–4F). All TKO mice injected with IFNgAb succumbed to
DENV infection, whereas those injected with Ctrl Ab survived
(Figure 4D). Additionally, TKOmice injectedwith IFNgAb showed
markedly increased weight loss (after day 2) and higher clinical
disease scores (after day 4) than TKO mice injected with Ctrl
Ab (Figures 4E and 4F). Although 100% of TKO mice treated
with IFNgAb and Ifnar1/ mice died following DENV infection,
there was a difference in the survival curves, with Ifnar1 mice
dying more rapidly (p < 0.0001, median survival: 4 days for
Ifnar1/ and 7 days for TKO + IFNgAb). Moreover, IFNgAb-
administered TKO mice showed a small delay in weight loss
(day 4, p < 0.0001) and rise in clinical disease score (days 3
and 4, p < 0.01 and p < 0.05, respectively) compared to Ifnar1
mice (Figures 4E and 4F), suggesting the existence of another
pathway besides IFN-g in protection against DENV infection in
TKO mice.
As splenocytes from DENV-infected TKO mice showed
modest upregulation of typical type I ISG genes by RNA-seq
at 24 hr, we next evaluated whether type I IFN signaling contrib-
uted to DENV resistance in TKO mice. We infected Ifnar1 and
TKO mice that were injected with IFNARAb alone or in combina-
tion with IFNgAb andmeasured DENV-associated morbidity and
mortality (Figures 4G–4I). Treatment with IFNARAb alone did not
increase DENV-associated mortality in TKO mice, but the com-
bination of IFNARAb and IFNgAb resulted in 100% mortality,
with a survival curve identical to Ifnar1 mice (Figure 4G).
Although TKO mice injected with IFNARAb alone survived
infection, they manifested similar degrees of weight loss as
Ifnar1 and TKO mice receiving both IFNARAb and IFNgAb for
3 days after infection before showing differential weight gain
(Figure 4H). Similarly, IFNARAb-administered TKO mice demon-
strated clinical disease comparable to TKO mice receiving both
IFNARAb and IFNgAb throughout the experiment (Figure 4I).
Collectively, these data indicate that IFN-g and, to a lesser
degree, type I IFNs are key components in the IRF-3, IRF-5,
and IRF-7-independent resistance pathway against severe
DENV infection.
IRF-1 Is Required for Resistance to Severe DENV
Infection in TKO Mice and Il12b Induction in
DENV-Infected Macrophages
The transcription factor IRF-1 can contribute to both type I
and II IFN signaling and is an important regulator of the
immune response to many viral infections (Brien et al., 2011;
Salkowski et al., 2000; Kimura et al., 1994; Dutia et al., 1999;
Taniguchi et al., 2001). Based on the RNA-seq analysis that
identified Irf1 and many IRF-1 target genes as significantly
upregulated in TKO mice during DENV infection, we hypothe-
sized that IRF-1 was an important component of the IRF-3-,
IRF-5-, and IRF-7-independent pathway of resistance to
severe DENV infection. To test this idea, Irf-1/ Irf-3/ Irf-5/
Irf-7/ QKO mice were generated for in vitro and in vivo DENV
infection experiments. DENV infection in vitro demonstrated
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that QKO macrophages sustain higher viral replication than
TKO cells at 24, 48, and 72 hr p.i., which approaches but
does not completely recapitulate the permissiveness seen in
Ifnar1/ cells (Figure 5A). WT and Ifnar1/ macrophages in-
fected with DENV upregulated Ifnb1 and Ifna4 gene expression
significantly more than TKO or QKO macrophages (Figures 5B
and S4A). Although WT cells induce Nos2, a typical IRF-1 target
gene, TKO macrophages expressed more Nos2 during DENV
infection than Ifnar1/ or QKO macrophages (Figure 5C). Up-
regulation of Nos2 appeared to be completely IRF-1 dependent
in the TKO background, as QKO cells expressed little to no
Nos2 transcript. In contrast to all other genes tested, macro-
phages from TKO mice expressed more IL12b than WT,
Ifnar1/, and QKO macrophages in response to DENV infec-
tion (Figure 5D). Consistent with in vitro data, QKO mice in-
fected with DENV in vivo were highly vulnerable to infection,
Figure 4. Effects of Blocking IL-12p40 or Type I or II IFN Signaling on TKO Resistance to DENV Infection
(A–C) TKO mice were infected with 53 106 FFU of DENV2 strain 221 with ADE and treated with IL-12p40 blocking or isotype control antibodies and lethality (A),
percent weight loss (B), and clinical scores (C) assessed daily for 10 days.
(D–I) TKO and Ifnar1/mice were infected with 53 106 FFU of DENV2 strain 221 and treated with IFN-g or isotype control monoclonal antibodies. Lethality (D),
percent weight loss (E), and clinical disease scores (F) were assessed daily for 10 days. TKO and Ifnar1/mice were infected as above and treated with IFNAR
blocking, IFNAR and IFN-g blocking, or isotype control monoclonal antibodies. Lethality (G), percent weight loss (H), and clinical disease scores (I) were assessed
daily for 10 days. Survival was compared between all groups by the log-rank test, and significance between groups is indicated by asterisks. Data are expressed
as mean percent weight loss and clinical scores that were compared daily by Student’s t test with Holm-Sidak correction (B and C) for multiple comparison or
one-way ANOVA (E and H) or non-parametric (Kruskal-Wallis) ANOVA with multiple correction (F and I).
Asterisks indicate statistically significant differences (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05).
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with survival curves, weight loss, and clinical scores virtually
identical to Ifnar1 mice (Figures 5E–5G). These results demon-
strate that IRF-1 is essential for the IRF-3, IRF-5, and IRF-7-in-
dependent pathway responsible for resistance to severe DENV
infection. DENV-infected WT mice produced significantly more
serum IFN-b and expressed higher levels of Mx1 in splenocytes
at 8 and 24 hr p.i. than TKO and QKO mice (Figures 5H and
S4C). In the majority of TKO and QKO mice, IFN-b was not
detectable during DENV infection. In contrast, significantly
higher levels of circulating IL-12p70 and IFN-g as well as sple-
nocyte upregulation of Ifng, Il12b, Irf1, and Nos2 were found at
24 hr p.i. in TKO mice (Figures 5I, 5J, and S4D–S4G).
Figure 5. Role of IRF-1 in the Host Response to DENV Infection In Vivo and in Macrophages
(A–D) BMDMs from indicated genotypes were infected with DENV2 S221 under ADE conditions (MOI = 0.5) and viral replication measured by FFA (A) and relative
gene expression of Ifnb1 (B), Nos2 (C), and Il12b (D) measured by qRT-PCR. Data represent the mean ± SD in one representative experiment performed in
triplicate and repeated three times. The dotted line represents the limit of detection of the assay. Gene expression levels were normalized to Rplp0 and displayed
as the fold increase compared to untreated BMDMs. Log10 viral FFU from gene-deficient andWTmacrophages were compared by two-way ANOVAwith Tukey’s
multiple comparisons tests. Gene expression studies were compared by one-way ANOVA with correction for multiple comparison.
(E–G) TKO, QKO, and Ifnar1/mice were infected with 53 106 FFU of DENV2 strain 221 with ADE, and lethality (E), percent weight loss (F), and clinical disease
scores (G) were assessed daily for 10 days. Survival was compared between all groups by the log-rank test and significance between groups indicated by
asterisks. Data are expressed as mean percent weight loss and clinical scores, respectively, that were compared daily by ANOVA (F) and non-parametric
(Kruskal-Wallis) ANOVA (G) with multiple correction. WT (n = 4 [8 hr], 14 [24 hr], 5 [48 hr]); TKO (n = 5 [8 hr], 10 [24 hr], 5 [48 hr]); and QKO (n = 4 [8 hr], 6 [24 hr],
5 [48 hr]) mice were infected as above and euthanized at indicated time points for serum collection. Serum levels of IFN-b (H), IL-12p70 (I), and IFN-g (J) were
measured by ELISA. Data are expressed as themean ± SEM andwere compared at each time point by ANOVAwith Tukey’s correction for multiple comparisons.
Asterisks indicate significant differences (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05).
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DISCUSSION
This study demonstrates that mice deficient in key SDTFs
regulating type I IFN secretion (IRF-3, IRF-5, and IRF-7) remain
resistant to severe DENV infection. Splenocytes from DKO and
TKO mice, but not the highly susceptible Ifnar1/ mice,
predominantly activate a transcriptional program compatible
with the IL-12/IFN-g/IRF-1 signaling pathway following DENV
infection, despite similar levels of baseline Irf-1 gene expression
in these three mouse strains. Consistent with the importance of
this pathway in the response to DENV, we found that inhibiting
IL-12 or IFN-g signaling with blocking antibodies or removal of
IRF-1 genetically was sufficient to increase the severity of
DENV disease in TKO mice. In vitro, DENV infection in TKO
BMDMs caused an IRF-1-dependent increase in the production
of Il12b, a gene that encodes for the IL-12p40 subunit of IL-12,
which is secreted bymacrophages and promotes IFN-g produc-
tion by NK and T cells. Additionally, both TKO mice and macro-
phages in vitro activate a low-level type I IFN response that acts
in concert with the IL-12/IFN-g/IRF-1 pathway to protect against
DENV infection. Collectively, our data demonstrate that IRF-1
stimulates both an IL-12/IFN-g and, to a lesser extent, a type I
IFN pathway in macrophages that protects against lethal DENV
infection in the absence of the canonical transcription factors
IRF-3, IRF-5, and IRF-7.
As Ifnar1/ mice are highly susceptible to DENV infection,
TKO mice were not expected to survive DENV challenge.
However, previous viral infections in TKO mice did not show
uniform results. Whereas WNV infection of TKO and Ifnar1/
mice produced similar mortality, murine norovirus (MNoV) infec-
tion showed delayed mortality in TKO compared to Ifnar1/
mice (Lazear et al., 2013). It remains unclear whether a
similar IL-12/IFN-g alternative pathway was stimulated in TKO
mice infected with WNV and MNoV. DKO mice infected with
chikungunya virus (CHIKV), another positive-sense, single-
stranded RNA virus, produced massive quantities of IFN-g
(Rudd et al., 2012), demonstrating that stimulation of IFN-g
responses in DKO mice is not unique to DENV. In the case of
MNoV, both IRF-1 and IFN-g contribute to macrophage resis-
tance to infection, and thus, if activated, the alternative pathway
of IFN-g activation may explain the difference in MNoV-induced
mortality in TKO and Ifnar1/ animals (Maloney et al., 2012). We
speculate that the susceptibility of TKO mice to viral infections
will depend in part on whether the alternative IFN-g response
is activated and the relative susceptibility of different viruses to
type I and II IFN responses.
IFN-g is less effective at mediating viral clearance from both
lymphoid and nonlymphoid tissues than type I IFNs yet still
protects mice from lethal DENV infection. The finding that
IFN-g can protect TKOmice against DENV infection is consistent
with previous studies demonstrating that mice with combined
deficiency of IFNAR and IFNGR are more susceptible to
DENV-associated mortality than animals with either defect alone
(Shresta et al., 2004). Blocking IFN-g signaling in DENV-infected
TKOmice resulted in 100%mortality, whereas blocking IL-12 led
to 50% mortality. Although IL-12 is a major stimulator of NK and
T cell IFN-g production, IL-12 blockade may produce a less
dramatic phenotype than IFN-g inhibition, because other cyto-
kines (e.g., IL-2, IL-15, IL-18, and type I IFNs) can stimulate an
IFN-g response (Schoenborn and Wilson, 2007; Okamura
et al., 1995, 1998). Despite the essential role of IFN-g for survival
of TKO mice during DENV infection, type I IFNs still contribute
significantly to DENV resistance, as anti-IFNAR blockade in
combination wtih IFN-g blockade in TKOmice exacerbatedmor-
tality to levels comparable to Ifnar1/mice. Additionally, block-
ing IFNAR alone during DENV infection of TKO mice resulted in
significant disease, as evidenced by the degree of weight loss
and increased clinical scores. Residual activation of type I IFNs
in TKO macrophages was detected in vitro by monitoring
expression of Ifnb1 and Mx1, a classical ISG. As we did not
detect significant upregulation of IFN-g in TKO BMDMs infected
with DENV, we suspect that low-level type I IFN activation, along
with potential direct activation of IRF-1 target genes such as
Nos2, may explain the difference in resistance to DENV infection
in vitro. This is supported by in vitro experiments showing that
the addition of IFNARAb increased the susceptibility of TKO
BMDMs to DENV infection.
We observed a shift from robust type I IFN production in WT
and Ifnar1/ mice to a significant type II IFN response in DKO
and TKO mice. This finding is consistent with previous publica-
tions showing that IRF-3 can act as amolecular switch regulating
Il12b transcription and IFN-g responses (Koshiba et al., 2013;
Negishi et al., 2012; Takeuchi, 2012). Our data suggest that
during DENV infection of macrophages, activation of canonical
IRF signaling via IRF-3 and/or IRF-7 suppresses IRF-1 stimu-
lated induction of Il12b and a type II IFN response. Many clini-
cally important viruses, including DENV, herpes viruses, and
the filoviruses Ebola and Marburg, suppress IRF-3 and/or
IRF-7 to antagonize IFN signaling and inhibit antiviral immunity
(Barro and Patton, 2007; MacMicking, 2012; Dalrymple et al.,
2015; Devaraj et al., 2007; Zhu et al., 2002; Anglero´-Rodrı´guez
et al., 2014; Cloutier and Flamand, 2010; Ronco et al., 1998;
Wang et al., 2009; Chang et al., 2009; Hahn et al., 2005; Basler
and Amarasinghe, 2009). Future studies will be needed to inves-
tigate whether the IRF-3, IRF-5, and IRF-7 alternative pathway of
type II IFN production is activated during these infections in hu-
mans and how it may impact pathogenesis and clinical disease
manifestations.
In summary, the present study revealed the existence of a late-
acting IRF-3-, IRF-5-, and IRF-7-independent pathway of innate
immunity that protects against lethal viral infection. This pathway
is mediated by IRF-1 activation of both type I and II IFNs, with a
predominant role for the IL-12/IFN-g signaling axis. Our work is
consistent with recent studies revealing that multiple transcrip-
tion factors exist to regulate the IFN system, which operates in
a time-, cell-type-, host-species-, or virus-specific manner.
Because of the effectiveness of immune evasion mechanisms
by specific viruses, these non-canonical pathways of the IFN
system may be important depending on the virus and the host
cell type or species.
EXPERIMENTAL PROCEDURES
Cells and Viruses
C6/36 Aedes albopictus mosquito cells were maintained in Leibovitz’s L15
medium (Invitrogen,) supplemented with 10% fetal bovine serum (FBS; Gemini
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Bio Products), penicillin, streptomycin, and HEPES (all from Invitrogen) at 28C
in the absence of CO2. S221 is a plaque-purified virus strain derived from the
Taiwanese DENV2 clinical isolate PL046 (obtained from Dr. Huan-Yao Lei,
National Cheng Kung University, Taiwan). The virus was propagated in C6/36
cells and quantified based on genomic equivalent (GE) by real-time RT-PCR
and FFUs as previously described (Yauch et al., 2009).
Mice and Infections
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). DKO and TKO mice have been described previously (Lazear et al.,
2013; Daffis et al., 2009) and were derived from single-knockout mice
provided by Dr. Tadatsugu Taniguchi (The University of Tokyo). Irf1/
mice (Matsuyama et al., 1993) were also obtained from Dr. Taniguchi.
Ifnar1/ mice were obtained from Dr. Wayne Yokoyama (Washington Uni-
versity, St. Louis, MO) via Dr. Carl Ware (La Jolla Institute for Allergy and
Immunology). All knockout mice were on the C57BL/6 genetic background.
Male and female mice age 5 to 6 weeks were infected intravenously with
5 3 106 FFU of DENV S221 under conditions of antibody-dependent
enhancement (ADE) (Zellweger et al., 2010). For ADE, mice were injected
with 10 mL immune serum 1 hr prior to DENV infection. Immune serum
was generated by inoculating Ifnar1/ mice with DENV2 strain PL046
(1 3 104 plaque-forming units [PFU]), followed by harvesting of serum on
day 30 p.i. The presence of DENV-specific immunoglobulin G (IgG) was
checked via ELISA and western blotting, and the absence of DENV by
qRT-PCR and FFA. DENV2 strain PL046 replicates but does not cause dis-
ease in these mice; virus is cleared by day 5–7 p.i. Mice were weighed and
scored for development of clinical signs on a daily basis. All animal experi-
ments were approved by the Animal Care Committee at La Jolla Institute
for Allergy and Immunology.
Measurement of DENV Burden in Mice
Mice were euthanized via isoflurane inhalation at different time points after
infection and perfused with 30mL PBS. Blood was collected via cardiac punc-
ture, and viral RNA in serumwas extracted using the QIAamp viral RNAMini kit
(QIAGEN). Tissues were harvested into RNAlater (QIAGEN) and homogenized
in RLT lysis buffer (QIAGEN) for 3 min using TissueLyser (QIAGEN) according
to the manufacturer’s instruction. Total RNA in tissues was extracted using the
RNeasy Mini kit (QIAGEN). Extracted RNA was stored at 80C until analysis.
qRT-PCR of DENV viral RNA in serum and tissueswas performed as previously
described (Yauch et al., 2009). A standard curve was generated with known
concentrations of DENV2 or 18S RNA. Virus titers in serum were expressed
as the log10 DENV2 GE/mL, and those in tissues were expressed as log10
DENV2 GE relative to 18S.
Blockade of Cytokines and Chemokines In Vivo
A dose of 0.5 mg functional grade (azide-free, sterile filtered, and with
endotoxin levels of <2.0 EU/mg) anti-mouse IFN-g antibody (clone XMG1.2),
anti-mouse IFNAR1 antibody (clone MAR1-5A3), anti-IL-12p40 (clone
C17.8), or isotype-matched control antibodies (all from Bio X Cell, West
Lebanon, NH) was administered via an intraperitoneal (i.p.) route and survival
monitored for 10 days after infection.
BMDM Culture and Infection
To generate BMDM, bone marrow from femur and tibia of 5- to 7-week-old
mice were isolated and cultured for 6–8 days in RPMI 1640 (10% fetal
bovine serum, penicillin, streptomycin, HEPES, and sodium pyruvate) in the
presence of 25 ng/mL murine macrophage-stimulating factor (M-CSF)
(PeproTech). On day 6–7 of culture, cells were re-plated at 500,000 cells
per well in a 12-well plate and infected with DENV2 strain S221 under ADE
conditions (MOI = 0.5 + 0.0833% (v/v) immune serum from DENV-
infected Ifnar1/ mice). Cells were harvested at 0, 4, 24, 48, and 72 hr p.i.
Infectious titer was determined by focus forming assay (FFA) on BHK21 cells.
For IFNAR blocking studies, an IFNARAb (clone MAR1-5A3) or isotype-
matched control antibody was added to BMDMs at 25 mg/mL 12 hr prior to
infection.
Serum Cytokine quantification by ELISA: Mice were sacrificed and blood
removed by cardiac puncture into Z-Gel tubes that were then centrifuged at
13,200 RPM for 15 min. Serum was aliquoted into single use vials and stored
at 80C. Serum IL-12p70 (mouse IL-12p70, 433604, BioLegend), IFN-g
(mouse IFN-g, 430804, BioLegend), and IFN-b (high sensitivity mouse IFN-b
PBL 42410-1) were measured using ELISA per manufacturer instructions
and quantified by generating standard curves in GraphPad Prism (GraphPad
Software).
qPCR
Total RNA was isolated by (Zymo) Quick-RNAMiniPrep treated in column with
DNase. RNA was then converted to cDNA by reverse transcription using
SuperScript III First-strand synthesis kit (Invitrogen, 18080051). qPCR
(SYBR GreenER, 172-5125, Bio-Rad) analysis was performed on an Applied
Biosystems 7300 real-time PCR system (Invitrogen).
RNA-Seq Library Preparation and Sequencing
For RNA sequencing analysis, total RNA was extracted from spleen tissue
using an RNeasy minikit (QIAGEN, 217004). Polyadenylated RNA was isolated
using the Poly(A)Purist MAG kit (Ambion, AM1922) and subsequently
fragmented using RNase III. 25 ng of each sample was used in the SOLiD Total
RNA-Seq Kit (Ambion, 4445374), per the manufacturer’s instructions, to
generate barcoded, strand-specific SOLiD libraries. The libraries were then
converted into SOLiD Wildfire compatible fragments using the 5500 WF
Conversion Primer Kit (PN 4478020) and the protocol supplied by Life Technol-
ogies (PN 4477188). Sequencing was performed with a SOLiD 5500WF
sequencer (Life Technologies), producing between 36 and 190 million sin-
gle-end reads with 35-nt lengths.
Data Analysis
Fastq files from RNA-seq experiments were mapped to mm10 using
spliced transcripts alignment to a reference (STAR) (Dobin et al., 2013; Heinz
et al., 2010) with default parameters and gene expression analyzed using hy-
pergeometric optimization of motif enrichment (HOMER) (Heinz et al., 2010)
with the parameter analyzeRepeats rna mm10 -count exons -noadj -pc
3 –condenseGenes followed by edgeR normalized abundance measure-
ments. Subset-specific expression was defined with a 2-fold difference in
expression between two experimental groups or time points. Genes with
less than 16 tag counts in all groups were defined as not expressed. To
map subset-specific peaks to gene expression, only expressed genes
were considered and used for gene ontology (GO) and Kyoto Encyclopedia
of Genes and Genomes (KEGG) annotation analysis with Database for Anno-
tation, Visualization, and Integrated Discovery (DAVID) (Huang et al., 2009a,
2009b). Cluster analysis of all differentially expressed genes was performed
using Cluster 3 (de Hoon et al., 2004) and Java Tree View. Number of clus-
ters to be used for k-means clustering was determined by analyzing signifi-
cant expression pattern changes using edgeR. To identify enriched tran-
scription-factor-binding motifs, findMotifs.pl in HOMER was used with the
standard background from position 300 to +50 relative to transcription start
site. Chord diagrams and network analysis was performed on significantly
upregulated genes at 6 hr p.i. (FC >1.5 and FDR <0.05) and 24 hr p.i.
(FC >2 and FDR <0.05) compared to baseline in each genotype using
NetworkAnalyst (Xia et al., 2014, 2015).
Statistical Analysis
Survival curves were analyzed using the log-rank (Mantel-Cox) test. Ordinary
one-way ANOVA with Tukey’s correction for multiple comparison was
used to compare genotypes on individual days for percent weight loss and
tissue and cell culture viral loads. Non-parametric (Kruskal-Wallis) ANOVA
with multiple correction was used to analyze in vivo clinical scores and
in vitro qPCR data. Statistical analysis was conducted using GraphPad Prism
(GraphPad Software) or Python. Values of p < 0.05 were considered
significant.
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